Innovative neuropeptide depression treatment to be developed

(Centre for Addiction and Mental Health) The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people with major depression. This approach represents a first-in-class therapeutic for depression and potentially other conditions, and ...